No Data
No Data
Humanwell Healthcare Gets Regulatory Nod for Parkinson's Disease Psychosis Drug Clinical Trials
Humanwell Healthcare (600079.SH): The clinical trial application for tartaric acid pimofanolin capsules has been approved.
Humanwell Healthcare (600079.SH) announced that its wholly-owned subsidiary, Wuhan Humanwell Pharmaceutical Co., Ltd., recently...
humanwell healthcare (600079.SH): HW071021 tablet has obtained the notice of drug clinical trial approval.
On September 3, Gelonhui announced that humanwell healthcare (600079.SH), a wholly-owned subsidiary of the company, wuhan humanwell healthcare innovative drugs research and development center co., LTD. (referred to as the "innovative drug research and development center"), recently received the drug clinical trial approval notice for HW071021 tablets issued by the National Medical Products Administration. The clinical trial of HW071021 tablets is intended for patients with advanced solid tumors.
Sinolink Securities: The large pharmaceutical sector is a key point in the mid-year report, and it is expected to see a overall recovery in the pharmaceutical sector in the second half of the year.
Looking ahead to the second half of the year, with the decline in the base, the recovery of procurement sentiment, and the stabilization of policy expectations, I am bullish on the recovery of demand for pharmaceutical and medical device products within hospitals, as well as the acceleration of performance growth. The pharmaceutical sector is expected to experience an overall reversal in the second half of the year.
Humanwell Healthcare Gets China Nod for Chemotherapy-Related Nausea Drug
Humanwell Healthcare Unit Gets UK Marketing Nod for Fentanyl Injection; Shares Jump 3%
No Data
No Data